Technology areas: Biotechnology & Pharmaceuticals • Chemistry & Materials
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
George Mason Research Foundation Inc. maintains a patent portfolio in the Biotechnology & Pharmaceuticals technology area, currently featuring 2 pending office actions. These actions are distributed across 2 distinct examiners, indicating a moderate level of variety in the individuals reviewing the foundation's applications. This distribution suggests that the foundation's research covers multiple specific sub-sectors within the broader biological and pharmaceutical fields.
The prosecution activity is further divided across 2 distinct art units. This separation into different art units implies that the technological focus of the 2 pending office actions is distinct enough to require different departmental expertise. GILL, RACHEL B is identified as the busiest examiner for the portfolio, currently managing 1 pending office action. This means that the workload is split, as no 1 examiner handles all of the active matters.
For a practitioner, the presence of 2 distinct examiners and 2 distinct art units requires a strategy that accounts for different examiner styles and departmental standards. While the total number of pending office actions is 2, the diversity in examiners and art units prevents a single point of failure. The fact that GILL, RACHEL B has 1 pending office action highlights that the foundation's Biotechnology & Pharmaceuticals portfolio is currently being evaluated through multiple independent channels.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| GILL, RACHEL B | 1 | 65.4% | +28.8% |
| AMARA, MOHAMED K | 1 | 75.8% | +29.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18705295 | Compositions and Methods for Diagnosis and Therapy of Viral Infection | GILL, RACHEL B | — |
| 18036137 | UV COATINGS AND DYES FOR LASER CAPTURE MICRODISSECTION | AMARA, MOHAMED K | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18705295 | Compositions and Methods for Diagnosis and Therapy of Viral Infection | GILL, RACHEL B | — |
| 18036137 | UV COATINGS AND DYES FOR LASER CAPTURE MICRODISSECTION | AMARA, MOHAMED K | — |
| Art Unit | Apps |
|---|---|
| 1671 | 1 |
| 1718 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18705295 | Compositions and Methods for Diagnosis and Therapy of Viral Infection | GILL, RACHEL B | 1671 | §101§102§112 | Non-Final OA | — | Pending | Apr 26, 2024 |
| 18036137 | UV COATINGS AND DYES FOR LASER CAPTURE MICRODISSECTION | AMARA, MOHAMED K | 1718 | §103§112 | Non-Final OA | — | Pending | May 09, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialGeorge Mason Research Foundation Inc. has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Rachel B Gill has the most, with 1 of George Mason Research Foundation Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
